You are here: Industry Insights > Poteligeo

News List

UK NICE recommends Kyowa Kirin’s Poteligeo for rare blood cancers Pharmaceutical-Technology
November 12, 2021
The UK National Institute for Health and Care Excellence (NICE) has recommended Kyowa Kirin’s humanised monoclonal antibody, Poteligeo (mogamulizumab), to treat adult patients...
NICE to reassess Kyowa Kirin’s Poteligeo pharmatimes
June 16, 2021
The National Institute for Health and Care Excellence (NICE) will reassess Kyowa Kirin’s rare blood cancer treatment Poteligeo after upholding an appeal launched by the companies and various charities.
SMC backs five new medicines for NHS use pharmatimes
June 09, 2021
The Scottish Medicines Consortium (SMC) has accepted five new medicines for use by NHS Scotland in its June 2021 decisions.
NICE rejects Kyowa Kirin’s rare blood cancer drug Poteligeo for NHS use pharmaceutical-technology
March 05, 2021
The UK’s drug pricing regulator the National Institute for Health and Care Excellence (NICE) has decided not to recommend Kyowa Kirin’s Poteligeo (mogamulizumab) for routine use in the National Health Service (NHS) in England and Wales.
NICE rejects NHS funding for Kyowa Kirin's Poteligeo pharmatimes
July 31, 2020
NICE is not recommending NHS funding for Kyowa Kirin's Poteligeo (mogamulizumab) as a treatment for mycosis fungoides or Sézary syndrome for adults who have had at least one previous systemic treatment.
Lancet publishes PhIII data on Kyowa Hakko’s Poteligeo pharmatimes
August 16, 2018
The Lancet has published data from Kyowa Hakko Kirin Co’s successful Phase III trial of immunotherapy Poteligeo underpinning its recent approval in the US to treat in patients with cutaneous T-cell lymphoma (CTCL).